DEA Slaps Another Year on Five Frankenstein Benzo Drugs
Published Date: 7/25/2025
Rule
Summary
The DEA is extending the temporary Schedule I status for five designer drugs—clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam—for one more year or until permanent rules are set. This means anyone making, selling, or using these drugs will keep facing strict legal controls and penalties. If you work with these substances, get ready to follow the same tough rules for now!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
One-Year Extension of Schedule I Controls
The DEA is extending the temporary Schedule I status of clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam for one year or until permanent rules are set. If you make, sell, import, export, research, teach about, chemically test, or possess these drugs, you will continue to be subject to the strict regulatory controls and administrative, civil, and criminal penalties that apply to Schedule I substances.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in